Last updated: 2026-09-09 07:37:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rezolute, Inc. (RZLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.41, with a market capitalization of $441.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.07 to $11.46. This page covers its latest market performance, valuation, price trends and company information.
$441.02M | |
$4.51 | |
$21.11 | |
$0.72 | |
$4.58 | |
666.49K | |
1.64M | |
-- | |
$11.46 | |
$1.07 | |
-- | |
-- |
Rezolute, Inc. (RZLT) last closed at $4.58 as of 2026-09-08 23:43:00, unchanged from the previous close of $4.58.
During the latest regular trading session, RZLT traded between $0.72 and $21.11, with a volume of 666.49K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Rezolute, Inc. (RZLT) moved from $4.62 to $4.41, representing a decline of 4.65% ($0.21).
The stock traded between $4.37 and $4.95 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 866.85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.1%
RZLT is currently trading at $4.41, placing it 32.1% of the way from its 52-week low of $1.07 to its 52-week high of $11.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rezolute, Inc. (RZLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.